ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "DMARDs"

  • Abstract Number: 1560 • 2012 ACR/ARHP Annual Meeting

    What Will Determine Adherence to Pharmaceutical Treatment for Rheumatoid Arthritis? A Systematic Review

    Annelieke Pasma1, Adriaan van 't Spijker2, Jan van Busschbach3, Johanna M.W. Hazes4 and Jolanda J. Luime5, 1Rheumatology, Erasmus MC University Medical Center, Rotterdam, Netherlands, 2Psychiatry, section Medical Psychology and Psychotherapy, Erasmus MC University Medical Center, Rotterdam, Netherlands, 3Medical Psychology and Psychotherapy, Erasmus MC - University Medical Center, Rotterdam, Netherlands, 4Rheumatology, Erasmus MC, Rotterdam, Netherlands, 5Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands

    Background/Purpose: In the early stages of Rheumatoid Arthritis (RA), adherence to the prescribed treatment is important to prevent irreversible joint damage. However, medication adherence rates…
  • Abstract Number: 773 • 2012 ACR/ARHP Annual Meeting

    Remission Rates with Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria

    Josef S. Smolen1, D. Aletaha2, D. Gruben3, J. D. Bradley4, S. H. Zwillich3, S. Krishnaswami3, B. Benda5 and C. Mebus6, 1Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna, Vienna, Austria, 2Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Pfizer Inc., Groton, CT, 4Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, 5Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, 6Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This analysis evaluated the rates…
  • Abstract Number: 2486 • 2012 ACR/ARHP Annual Meeting

    Radiographic, Clinical and Functional Comparison of Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis

    Eun Bong Lee1, Roy Fleischmann2, Stephen Hall3, Ronald F. van Vollenhoven4, John Bradley5, David Gruben6, Tamas Koncz7, Sriram Krishnaswami5, Gene Wallenstein6, Samuel H. Zwillich5, Bethanie E. Wilkinson6 and the ORAL Start Investigators8, 1Seoul National University, Seoul, South Korea, 2Metroplex Clinical Research Center, Dallas, TX, 3Cabrini Medical Centre, Melbourne, Australia, 4Karolinska Institute, Stockholm, Sweden, 5Pfizer Inc, Groton, CT, 6Pfizer Inc., Groton, CT, 7Pfizer Inc., New York, NY, 8Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This Phase 3, 24-mo study (ORAL…
  • Abstract Number: 1573 • 2012 ACR/ARHP Annual Meeting

    Baseline Screening Recommendations for Rheumatoid Arthritis Patients Treated with Disease Modifying Anti-Rheumatic Drugs:  Does an Educational Intervention Change Practice in an Outpatient Clinic?

    Debra C. Lloyd1, John N. Mecchella2 and Daniel Albert3, 1Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, 2Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, 3Rheumatology, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Lebanon, NH

    Background/Purpose: In 2008, the American College of Rheumatology (ACR) developed recommendations for use of non-biologic and biologic DMARDs in the treatment of rheumatoid arthritis (RA). …
  • Abstract Number: 566 • 2012 ACR/ARHP Annual Meeting

    Effect of TNF Antagonists On Radiographic Progression in Psoriatic Arthritis: Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Radjiv Goulabchand1, Gael Mouterde1, Cédric Lukas2, Thomas Barnetche3, Jacques Morel1 and Bernard Combe1, 1Rheumatology, Montpellier 1 University, Lapeyronie Hospital, Montpellier, France, 2Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, 3Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France

    Background/Purpose: Psoriatic arthritis (PsA) can cause important structural damages which can lead to disability. TNF antagonists have shown their clinical efficacy in PsA, but only…
  • Abstract Number: 2490 • 2012 ACR/ARHP Annual Meeting

    Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis

    K. L. Winthrop1, H. Valdez2, E. Mortensen3, R. Chew4, S. Krishnaswami5, T. Kawabata5 and R. Riese4, 1Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, 2Pfizer Inc., New York, NY, 3Global Medical Affairs, Pfizer Inc., Collegeville, PA, 4Pfizer Inc., Groton, CT, 5Pfizer Inc, Groton, CT

    Background/Purpose: Patients (pts) with RA are at increased risk for herpes zoster (HZ) i.e. ‘shingles'. Tofacitinib, a novel oral Janus kinase inhibitor investigated as a…
  • Abstract Number: 1297 • 2012 ACR/ARHP Annual Meeting

    Tofacitinib and Adalimumab Achieve Similar Rates of Low Disease Activity in Rheumatoid Arthritis — Lack of Improvement in Disease Activity Score by 3 Months Predicts Low Likelihood of Low Disease Activity At 1 Year

    Ronald F. van Vollenhoven1, Sriram Krishnaswami2, Birgitta Benda3, David Gruben4, Bethanie Wilkinson4, Charles A. Mebus4, Samuel H. Zwillich2 and John Bradley2, 1Karolinska Institute, Stockholm, Sweden, 2Pfizer Inc, Groton, CT, 3Pfizer Inc., Collegeville, PA, 4Pfizer Inc., Groton, CT

    Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This post-hoc analysis of the…
  • Abstract Number: 491 • 2012 ACR/ARHP Annual Meeting

    Predictors of Initiating Biologic Monotherapy in Biologic Naïve Patients with Rheumatoid Arthritis (RA) in a US Registry Population

    Dimitrios A. Pappas1, George W. Reed2, Ani John3, Ashwini Shewade3, Katherine C. Saunders4, Jenny Devenport5, Jeffrey D. Greenberg6 and Joel M. Kremer7, 1Columbia University, New York, NY, 2University of Massachusetts Medical School, Worcester, MA, 3Genentech Inc., South San Francisco, CA, 4Corrona, LLC., Southborough, MA, 5Genentech, South San Francisco, CA, 6Rheumatology, NYU Hospital for Joint Diseases, New York, NY, 7Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: Published data have shown that approximately one-third of patients with RA are treated with biologic (Bio) monotherapy (MT) (without concomitant DMARD) and a considerable…
  • Abstract Number: 2480 • 2012 ACR/ARHP Annual Meeting

    Disease-Modifying Antirheumatic Drug Use and Toxicities Among Elderly Patients with Rheumatoid Arthritis

    Rebecca L. Manno1, Dimitrios A. Pappas2, Katherine C. Saunders3, George Reed4, Shannon Grant5 and Clifton O. Bingham III6, 1Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 2New York Presbyterian Hospital, Columbia University, College of Physicians & Surge, New York, NY, 3Corrona, LLC., Southborough, MA, 4Division of Behavioral and Preventive Medicine, University of Massachusetts Medical School, Worcester, MA, 5Axio Research LLC, Seattle, WA, 6Department of Medicine, Johns Hopkins University, Baltimore, MD

    Background/Purpose: The aging population has resulted in large numbers of older individuals requiring treatment for rheumatoid arthritis (RA). We sought to describe the clinical characteristics…
  • Abstract Number: 1298 • 2012 ACR/ARHP Annual Meeting

    Improvement of Treatment Outcome of Rheumatoid Arthritis with Salazosulfapyridine by Pharmacogenetic Approach

    Shunichi Kumagai1, Yoshiaki Hagiwara2, Yoshihide Ichise1, Sho Sendo3, Nobuhiko Okada1, Jun Saegusa4 and Goh Tsuji5, 1Center of rheumatic diseases, Shinko hospital, Kobe, Japan, 2Department of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, 3Center of rheumatic diseases, Shinko Hospital, Kobe, Japan, 4Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 5Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan

    Background/Purpose: Salazosulfapyridine (SASP) is acetylated in liver by N-acetyltransferase2 (NAT2) in the track of metabolism. Previous studies have shown that genotyping of NAT2 is adequate…
  • Abstract Number: 473 • 2012 ACR/ARHP Annual Meeting

    The Addition of Another Disease-Modifying Anti-Rheumatic Drug to Methotrexate in Place of Infliximab Reduces the Flare Rate During 2 Years After Infliximab Discontinuation in Patients with Rheumatoid Arthritis

    Hideto Kameda1, Takahiko Kurasawa1, Hayato Nagasawa2, Koichi Amano3 and Tsutomu Takeuchi4, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Saitama Medical Ctr, Kawagoe, Japan, 3Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 4Rheumatology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: The treatment strategy for rheumatoid arthritis (RA) should be divided into remission-induction phase and its maintenance phase. To date, the usefulness of the combination…
  • Abstract Number: 2485 • 2012 ACR/ARHP Annual Meeting

    Tofacitinib, an Oral Janus Kinase Inhibitor: Analyses of Efficacy and Safety of 10 versus 5mg Twice Daily in a Pooled Phase 3 and Long-Term Extension Rheumatoid Arthritis Population

    S. Cohen1, S. Krishnaswami2, B. Benda3, R. Riese2, M.G. Boy4, D. Gruben4, G. Wallenstein5, C. A. Mebus4, S. H. Zwillich2 and J. D. Bradley6, 1Metroplex Clinical Research Centre, Dallas, TX, 2Pfizer Inc., Groton, CT, 3Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, 4Pfizer Inc, Groton, CT, 5Pfizer Inc, New York, NY, 6Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. Phase (P) 3 studies demonstrated…
  • Abstract Number: 1277 • 2012 ACR/ARHP Annual Meeting

    Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study

    D. van der Heijde1, Y. Tanaka2, Roy Fleischmann3, Edward Keystone4, Joel M. Kremer5, C. Zerbini6, M. H. Cardiel7, S. B. Cohen8, P. T. Nash9, Y. Song10, D. Tegzova11, B. Wyman12, D. Gruben12, B. Benda13, G. Wallenstein14, S. Krishnaswami12, S. H. Zwillich12, J. Bradley15, C. A. Connell16 and ORAL Scan Investigators17, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Metroplex Clinical Research Center, Dallas, TX, 4Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, Canada, 5The Center for Rheumatology, Albany Medical College, Albany, NY, 6CEPIC – Centro Paulista de Investigação Clínica, São Paulo-SP, Sao Paulo, Brazil, 7Centro de Investigacion Clinica de Morelia, Morelia, Mexico, 8Metroplex Clinical Research Centre, Dallas, TX, 9Rheumatology Research Unit, Nambour Hospital, Sunshine Coast, Australia, 10Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 11Institute of Rheumatology, Prague, Czech Republic, 12Pfizer Inc., Groton, CT, 13Clinical Development & Medical Affairs, Pfizer Inc., Collegeville, PA, 14Pfizer Inc, New York, NY, 15Worldwide Pharmaceutical Development, Pfizer Inc., Groton, CT, 16Pfizer Inc, Groton, CT, 17Groton

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This 24‑month (Mo) Phase 3…
  • Abstract Number: 370 • 2012 ACR/ARHP Annual Meeting

    Characteristic of the Japanese Patients with Rheumatoid Arthritis (RA) of Rapid Radiographic Progression (RRP) Treated with Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (the 1st report of Apple Survey)

    Akitomo Okada1, Atsushi Kawakami2, Takaaki Fukuda3, Toshihiko Hidaka4, Tomonori Ishii5, Yukitaka Ueki6, Takao Kodera7, Munetoshi Nakashima8, Yuichi Takahashi9, Seiyo Honda10, Yoshiro Horai2, Tomohiro Koga1, Ryu Watanabe11, Hiroshi Okuno12 and Katsumi Eguchi13, 1Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan, 4Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, 5Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, 6Sasebo Chuo Hospital, Sasebo, Japan, 7Tohoku Kosei Nenkin Hospital, Sendai, Japan, 8Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 9Yu Family Clinic, Sendai, Japan, 10Kurume University School of Medicene, Kurume, Japan, 11Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, 12Tohoku University Hospital, Sendai, Japan, 13Sasebo City General Hospital, Sasebo, Nagasaki, Japan

    Background/Purpose: There has been few epidemiological report of longitudinal radiographic progression in rheumatoid arthritis (RA) patients captured in daily practice. In 20 related-centers of the…
  • Abstract Number: 2172 • 2012 ACR/ARHP Annual Meeting

    An Update of Management of Coccidioidomycosis in Patients On Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs

    Susan Knowles1, Dominick Sudano1, Sara Taroumian2, Neil M. Ampel3, John Galgiani4, Jeffrey R. Lisse1 and Susan E. Hoover5, 1Department of Rheumatology, University of Arizona, Tucson, AZ, 2Department of Rheumatology, University of California, Los Angeles, Los Angeles, CA, 3Infectious Disease, University of Arizona, Tucson, AZ, 4Valley Fever Center for Excellence, Tucson, AZ, 5Infectious Diseases, University of Arizona, Tucson, AZ

    Background/Purpose: Coccidioidomycosis (valley fever) is an endemic fungal infection in the Southwestern United States which typically causes a self-limited pulmonary illness. Patients with rheumatic disease…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology